Apremilast

• Psoriatic Arthritis
• Plaque Psoriasis
• Behçet's Disease
• Oral Ulcers

Apremilast (brand name Otezla) is an oral, small-molecule phosphodiesterase 4 (PDE4) inhibitor approved for adults with active psoriatic arthritis, moderate-to-severe plaque psoriasis, and oral ulcers associated with Behçet's disease. Unlike injectable biologics, apremilast is taken by mouth twice daily, requires no laboratory pre-screening for tuberculosis or hepatitis, and does not produce broad immunosuppression. For patients who prefer pills to injections, who have failed topical therapy, or who are not candidates for systemic biologics, apremilast offers a meaningful middle ground in the inflammatory disease treatment ladder. It is generally well tolerated, although gastrointestinal symptoms in the first two weeks are common and require a deliberate titration schedule that almost every patient must complete before reaching the full daily dose.

Mechanism of Action

Apremilast works by selectively inhibiting PDE4, an intracellular enzyme abundant in T-cells, monocytes, neutrophils, dendritic cells, and keratinocytes. PDE4 normally degrades cyclic adenosine monophosphate (cAMP), an intracellular second messenger that broadly modulates immune signaling. By blocking PDE4, apremilast allows cAMP to accumulate inside immune cells, which then dampens the transcription of pro-inflammatory cytokines including TNF-alpha, interferon-gamma, IL-17, IL-23, IL-22, and chemokines that recruit additional inflammatory cells, while modestly increasing the anti-inflammatory cytokine IL-10. This shifts the local cytokine milieu away from a Th17-dominant inflammatory pattern.

The net effect is a measured downshift of the Th1 and Th17 inflammatory pathways that drive both psoriatic skin plaques and the synovitis of psoriatic arthritis. Because PDE4 is regulated rather than blocked at a single cytokine bottleneck, apremilast's clinical effect is more gradual and less dramatic than biologics like adalimumab or ustekinumab, but it carries no boxed warning for serious infection or malignancy and does not require periodic injection visits. The same cAMP elevation in central nervous system tissue likely explains the medication's small but real association with depressed mood and weight loss, which the FDA highlights in its prescribing information available through DailyMed. Effects on the gastrointestinal tract are also mediated by intestinal PDE4 inhibition, which accelerates motility and produces the diarrhea and nausea that mark the first two weeks. Skin clearance lags lab markers because epidermal turnover requires several weeks; patients should be counseled that visible improvement usually emerges over 8 to 16 weeks rather than days.

Clinical Use

In psoriatic arthritis, apremilast is typically positioned after NSAIDs and conventional disease-modifying agents such as methotrexate but before TNF inhibitors. Many patients with mild-to-moderate joint involvement, contraindications to immunosuppression, or active hepatitis B exposure choose apremilast specifically to avoid TNF-blocker screening burdens and the lifelong infection-monitoring that biologics impose. In plaque psoriasis covering 5 to 20 percent of body surface area, apremilast offers PASI-75 response rates around 30 percent at 16 weeks - lower than IL-17 or IL-23 blockers, but with an oral route many patients prefer.

For Behçet's-related oral aphthous ulcers, apremilast significantly reduces ulcer count and pain, and is often considered when colchicine alone is inadequate. The American College of Rheumatology and dermatology guidelines both regard apremilast as a reasonable second-line systemic option for plaque psoriasis. Comparative trials suggest apremilast underperforms biologics for severe disease but matches or exceeds older oral agents like methotrexate for tolerability and convenience, with no need for periodic liver biopsies or alcohol counseling. Patients most likely to do well are those with limited but stubborn plaques, scalp or palmoplantar disease that resists topicals, dactylitis or enthesitis dominating their psoriatic arthritis presentation, or lifestyle factors that make injections impractical. Apremilast can also be a useful bridge while a patient awaits insurance approval for a biologic, or a maintenance option after biologic failure when further immunosuppression is undesirable. Patients with significant depression history, recent unintentional weight loss, eating disorders, or fragile nutritional status may be better served by another agent. The drug is rarely combined with biologics; if response to apremilast monotherapy is inadequate after four to six months, switching is preferred over adding a biologic.

How to Take It

Apremilast is dispensed in a starter pack that titrates the dose over five days to reduce gastrointestinal side effects. The schedule begins with 10 mg in the morning on day one and gradually builds, by 10 mg increments at each dose, to a maintenance regimen of 30 mg twice daily by day six. Tablets may be taken with or without food and should be swallowed whole. If a dose is missed within several hours, take it as soon as remembered; if it is nearly time for the next dose, skip the missed one rather than doubling up.

The first one to two weeks are typically the most uncomfortable. Loose stools, nausea, abdominal cramping, and headache are common but usually resolve within the first month. Taking each dose with a small meal or snack and staying well hydrated often blunts these symptoms. Loperamide may be used short-term for diarrhea but should not become a chronic strategy; if diarrhea persists beyond two weeks at the full dose, the prescriber may permit a temporary dose reduction back to 30 mg once daily. Store tablets at room temperature, away from moisture and direct light. Patients should not stop and restart abruptly without re-titration if more than a few doses are missed in a row, as the original gastrointestinal symptoms can return in full force.

Monitoring and Follow-Up

Apremilast does not require routine laboratory monitoring - no scheduled CBC, liver panel, or lipid checks are mandated by the label. However, weight and mood should be tracked at every visit. A baseline weight is recorded before starting and reassessed at 3, 6, and 12 months. Unintentional loss of more than 5 percent of body weight, particularly in patients who began therapy underweight, prompts a serious discussion about discontinuation. A baseline depression screen using the PHQ-9 is reasonable, with reassessment at 1 month and again at 3 months and at any visit where mood symptoms are reported.

Response in the joints is typically assessed at 16 to 24 weeks; patients who have not achieved meaningful symptom reduction by then are unlikely to benefit from continued use. For skin disease, photographs and PASI or BSA assessment at 16 weeks help guide whether to continue, switch, or escalate. Although routine labs are not required, many clinicians check a CBC and metabolic panel annually as part of general health maintenance, and patients with comorbid conditions may need additional surveillance based on their other medications. Blood pressure, fasting lipids, and HbA1c are typically tracked because psoriasis and psoriatic arthritis are themselves associated with cardiometabolic comorbidity, and aggressive cardiovascular risk reduction is part of comprehensive care. Patients on long-term apremilast benefit from periodic reassessment of whether the drug is still needed at full dose; some achieve sustained remission and tolerate dose reduction.

Special Populations

Elderly patients tolerate apremilast similarly to younger adults but may experience more dehydration from diarrhea; baseline kidney function should be checked before starting. In severe renal impairment with creatinine clearance under 30 mL/min, the dose is reduced to 30 mg once daily and the titration uses only morning doses. No dose adjustment is required for hepatic impairment. Pregnancy data are limited; animal studies have shown embryofetal loss, and an exposure registry maintained by the manufacturer captures outcomes when the drug is used inadvertently in pregnancy. Effective contraception is recommended during therapy and women should be counseled to report suspected pregnancy promptly.

Apremilast is not approved in patients under 6 years of age, and pediatric use should follow specialist guidance. Lactation data are sparse, and most clinicians recommend against nursing while on therapy. Patients with a history of major depression, bipolar disorder, or suicidal ideation deserve careful counseling and, where appropriate, comanagement with a mental health clinician before initiation. Drug interactions are limited; the most important is avoidance of strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and phenobarbital, which can lower apremilast levels enough to abolish its effect. St. John's wort should also be avoided. The drug does not meaningfully interact with oral contraceptives, methotrexate, NSAIDs, or commonly used cardiovascular medications.

When to Contact Your Doctor

Call the office promptly for new or worsening depression, hopelessness, suicidal thoughts, or behavior changes that family members notice. Diarrhea that becomes severe, persistent beyond two weeks, contains blood, or causes lightheadedness and weight loss requires evaluation. Unintended weight loss greater than 5 percent of baseline, fever or signs of infection that do not resolve, severe abdominal pain, or hypersensitivity reactions including rash, swelling, or wheezing all warrant urgent contact. Stop the medication and seek emergency care for any signs of anaphylaxis, throat swelling, or difficulty breathing.

If you would like to discuss whether apremilast is the right choice for your psoriasis or psoriatic arthritis, contact us or schedule a visit with our internal medicine team.